Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.60 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.59 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475801 | 0.78 | GABRA1 (0.69) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL28289153 | 0.78 | GABRA1 (0.69) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL376662 | 0.78 | GABRA1 (0.69) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| Hydrochloric Acid SCHEMBL29008098 | 0.77 | GABRA1 (0.67) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| Hydrochloric Acid SCHEMBL30417898 | 0.77 | GABRA1 (0.67) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL15080244 | 0.77 | KDM4E (0.51) | CYP1A2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL7284420 | 0.76 | GABRA1 (0.78) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL30417619 | 0.76 | GABRA1 (0.78) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL28287752 | 0.76 | GABRA1 (0.66) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL28289180 | 0.76 | GABRA1 (0.66) | GABRA1GABRB2GABRB1GABRA3CLEC4M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4043439-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-03-12 | — | — | EP | claimed |
| EP-3464243-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-02-12 | — | — | EP | claimed |
| US-11274081-B2 | Process for the synthesis of ivacaftor | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-03-15 | — | — | US | claimed |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-15 | — | — | US | claimed |
| EP-4556008-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3464243-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-02-12 | — | — | EP | disclosed |
| EP-3470063-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMA (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024151425-A1 | COMPOUNDS AND METHOD FOR TREATING HIV INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12024491-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024491-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230364073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-16 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007079139-A2 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070032522-A1 | Antiviral agents | VIROBAY, INC. | 2007-02-08 | — | — | US | disclosed |
| US-4659734-A | BACTERICIDES, FUNGICIDES | NIPPON SHINYAKU CO., LTD. (JP) | 1987-04-21 | — | — | US | disclosed |
| EP-0058392-B1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
| EP-0058392-A1 | Substituted carboxylic acid derivatives | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274081-B2 | Process for the synthesis of ivacaftor | IDO1, IDO2, SLC10A2 | GABRA1 946/4885GABRB2 1587/4885GABRB1 1446/4885 |
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | GABRA1 3235/4885GABRB2 2513/4885GABRB1 2699/4885 |
| US-12024491-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SLC47A2, SCNN1B | GABRA1 867/4885GABRB2 509/4885GABRB1 460/4885 |
| US-20230364073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | CFTR, CLCN2, CLIC1 | GABRA1 511/4885GABRB2 658/4885GABRB1 625/4885 |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | IDO1, SLC10A2, IDO2 | GABRA1 952/4885GABRB2 1472/4885GABRB1 1357/4885 |
| US-20070032522-A1 | Antiviral agents | MAVS, HAVCR2, EIF2AK2 | GABRA1 4600/4885GABRB2 4547/4885GABRB1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.